Skip to main content

Table 2 Clinical characteristics of patients at 24-week after medication treatment (n = 30 for each group)

From: Liraglutide and Metformin alone or combined therapy for type 2 diabetes patients complicated with coronary artery disease

Variables Section 1 Section 2
Liraglutide monotherapy Metformin monotherapy P Liraglutide (1.8 mg/d) monotherapy Liraglutide plus Metformin dual therapy P
BMI (kg/m2) 28.37 ± 1.72 28.70 ± 1.87 0.480 28.65 ± 1.77 28.42 ± 1.74 0.614
FPG
c
6.0 ± 1.2 6.2 ± 1.0 0.701
0.608
6.0 ± 1.2 6.2 ± 1.0 0.486
0.633
 % 6.8 ± 0.8 6.9 ± 0.7   6.8 ± 0.9 6.7 ± 0.7  
 mmol/L 51 ± 9 52 ± 8   51 ± 10 50 ± 8  
PPG (mmol/L) 7.9 ± 3.3 8.2 ± 3.5 0.734 7.9 ± 3.4 7.7 ± 3.2 0.815
TG (mmol/L) 2.4 ± 0.4 2.6 ± 0.5 0.093 2.5 ± 0.4 2.4 ± 0.5 0.396
TC (mmol/L) 5.4 ± 0.7 5.7 ± 0.8 0.128 5.7 ± 0.7 5.3 ± 0.6 0.021
LDL-C (mmol/L) 3.5 ± 0.5 3.8 ± 0.6 0.040 3.7 ± 0.7 3.4 ± 0.6 0.080
CRP (mg/L) 5.1 ± 1.5 7.2 ± 1.7 <0.001 5.5 ± 1.6 5.2 ± 1.3 0.429
SBP (mmHg) 134 ± 7 141 ± 7 <0.001 135 ± 7 132 ± 8 0.127
DBP (mmHg) 86 ± 6 91 ± 6 0.002 87 ± 6 86 ± 5 0.486
LVEDD (mm) 46 ± 6 50 ± 7 0.021 52 ± 8 48 ± 7 0.044
EF (%) 53 ± 5 50 ± 6 0.040 52 ± 5 54 ± 6 0.166
E/A ratio 0.92 ± 0.08 0.77 ± 0.09 <0.001 0.88 ± 0.08 0.93 ± 0.09 0.027
  1. Data are mean ± SD; Abbreviations: BMI body mass index, TG triglyceride, TC total cholesterol, LDL-C low-density lipoprotein cholesterol, PPG postprandial glucose, SBP systolic blood pressure, DBP diastolic blood pressure, CRP C-reactive protein, LVEDD left ventricular end-diastolic diameter, EF ejection fraction